It has also been proposed that cardiovascular medication, in particular, inhibitors of the Renin-Angiotensin-Aldosterone system (RAASi) elevate serum ACE2 activity, potentially contributes to the mortality of COVID-19 [4, 6, 7]. This evidence concerns the gene ACE2 and COVID-19.